Skip to main content
World Today News
  • Home
  • News
  • World
  • Sport
  • Entertainment
  • Business
  • Health
  • Technology
Menu
  • Home
  • News
  • World
  • Sport
  • Entertainment
  • Business
  • Health
  • Technology
Retatrutide: Two-Thirds of Obese Patients Achieve 15% Weight Loss and 50% Pain Drop in Knee OA Trials

Retatrutide: Two-Thirds of Obese Patients Achieve 15% Weight Loss and 50% Pain Drop in Knee OA Trials

November 20, 2026 Health Desk Health

About two-thirds of obese patients receiving retatrutide achieved at least 15% weight loss and a 50% drop in knee osteoarthritis pain in clinical trials.

Knee osteoarthritis pain dropped by at least 50% for about two-thirds of trial participants given an experimental weight-loss drug, according to The New England Journal of Medicine.

Key Clinical Takeaways:

  • Two phase 3 trials tested weekly injections of retatrutide on over 1,000 obese patients without type 2 diabetes.
  • Participants on the highest doses lost roughly one-fifth of their body weight over 68 to 80 weeks.
  • Researchers observed significant reductions in joint pain, blood pressure, and systemic inflammation compared to placebos.

Osteoarthritis involves the wear of articular cartilage, which cushions bone ends and absorbs mechanical load in joints like the knee. Obesity places severe mechanical stress on these structures, accelerating joint degeneration and triggering chronic pain, swelling, and stiffness. Futura reported that researchers tested the experimental molecule retatrutide to evaluate whether substantial weight reduction could ease these symptoms.

Retatrutide is an injectable triple-hormone receptor agonist developed by Eli Lilly that activates the GLP-1, GIP, and glucagon receptors, Marie Claire reported. It follows earlier single and dual agonists such as semaglutide and tirzepatide. The drug is currently being evaluated in clinical trials for chronic weight management, moderate-to-severe obstructive sleep apnea, and knee osteoarthritis.

The clinical evaluation involved two distinct phase 3 trials directed by Northwestern University. The TRIUMPH-4 study followed 445 participants for 68 weeks, administering 9 mg or 12 mg doses of retatrutide or a placebo. A second trial, designated TRIUMPH-1-OA, enrolled 574 participants across 4 mg, 9 mg, and 12 mg dosing arms over 80 weeks.

Trial Arm Duration Sample Size Pain Score Reduction
TRIUMPH-4 (9 mg/12 mg) 68 weeks 445 3.96 / 3.74 (vs 2.12 placebo)
TRIUMPH-1-OA (4 mg/9 mg/12 mg) 80 weeks 574 3.22 / 3.48 / 3.64 (vs 1.87 placebo)

Pooled data from the trials indicated that roughly two-thirds of patients receiving the active treatment achieved at least a 15% reduction in body weight alongside a 50% drop in knee pain scores. Participants taking a placebo showed a pain score reduction of about 38%, according to university findings reported by Marie Claire. Beyond weight loss and pain relief, investigators noted improvements in blood pressure, lipid panels, and systemic inflammation.

“This study confirms what the surgeons have known for years: weight management is an important component of the treatment of knee osteoarthritis, particularly in patients who are overweight or obese,” said Dr. Timothy Gibson, an orthopedic surgeon, speaking to Medical News Today as cited by Futura.

While mechanical unloading explains a large portion of the symptom relief, researchers are investigating whether the molecule provides direct anti-inflammatory benefits within joint tissues. Genetic engineer Şebnem Ünlüişler noted to Futura that the multi-receptor activity might confer metabolic advantages, though direct impacts on synovial inflammation require further isolation.

“It is important to look at whether the reduction of joint inflammation, in addition to the decrease in load, is also important. So, this is, I think, a first step, and I’ve been in the field of osteoarthritis for a long time, and I think this opens the door for many, many additional studies to better understand this pathology,” said Dr. Thomas Schnitzer, principal study author and professor of physical medicine and rehabilitation, anesthesiology, and rheumatology at Northwestern University Feinberg School of Medicine, via a university release cited by Marie Claire, according to Marieclaire.

Specialists emphasize that future investigations must determine whether the structural progression of cartilage degradation is altered and whether the therapy reduces the eventual necessity of joint replacement surgeries. Additional safety monitoring will assess whether rapid weight reduction compromises skeletal muscle mass and joint stability over multi-year horizons.

Eli Lilly and Company, founded in 1876 in Indianapolis by a Union army veteran and pharmaceutical chemist, was the first company to mass-produce insulin and later the polio vaccine.

It also brought the first GLP-1 receptor agonist, exenatide, to market in 2005, establishing an early foothold in the metabolic drug class now central to retatrutide’s mechanism. In November 2025, it became the first health-care company to reach a $1 trillion market capitalization, ranking as the most valuable pharmaceutical company worldwide.

Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.

More on this story: Stopping GLP-1 Weight-Loss Drugs Doubles Cardiovascular Risk · Cleveland Clinic: Adults Stopping GLP-1 Medications Regain Most Weight

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X

Related reading

  • I Tested the Brooks Adrenaline GTS 26: A Stability Shoe That Balances Support and Comfort for Walking
  • Study Proposes Allergy Origins Lie in Barrier Cell Mitochondrial Failure, Not Immune System

Related

GLP-1

Search:

World Today News

World Today News is your trusted source for global journalism — breaking headlines, in-depth analysis, and reporting from around the world.

Quick Links

  • Privacy Policy
  • About Us
  • Accessibility statement
  • California Privacy Notice (CCPA/CPRA)
  • Contact
  • Cookie Policy
  • Disclaimer
  • DMCA Policy
  • Do not sell my info
  • EDITORIAL TEAM
  • Terms & Conditions

Browse by Location

  • GB
  • NZ
  • US

Connect With Us

© 2026 World Today News. All rights reserved. Your trusted global news source directory.
For contact, advertising, copyright, issues email: [email protected]

Privacy Policy Terms of Service